Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.31
HSP's Cash to Debt is ranked higher than
59% of the 926 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. HSP: 0.31 )
HSP' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: 0.31

Equity to Asset 0.52
HSP's Equity to Asset is ranked higher than
61% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. HSP: 0.52 )
HSP' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.65
Current: 0.52

0.28
0.65
Interest Coverage 0.19
HSP's Interest Coverage is ranked higher than
55% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.63 vs. HSP: 0.19 )
HSP' s 10-Year Interest Coverage Range
Min: 0.19   Max: 9999.99
Current: 0.19

0.19
9999.99
F-Score: 7
Z-Score: 3.75
M-Score: -2.78
WACC vs ROIC
6.88%
9.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.85
HSP's Operating margin (%) is ranked higher than
78% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.10 vs. HSP: 10.85 )
HSP' s 10-Year Operating margin (%) Range
Min: 0.41   Max: 16.17
Current: 10.85

0.41
16.17
Net-margin (%) 7.48
HSP's Net-margin (%) is ranked higher than
77% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. HSP: 7.48 )
HSP' s 10-Year Net-margin (%) Range
Min: -0.23   Max: 11.4
Current: 7.48

-0.23
11.4
ROE (%) 10.63
HSP's ROE (%) is ranked higher than
82% of the 895 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. HSP: 10.63 )
HSP' s 10-Year ROE (%) Range
Min: -0.31   Max: 24.74
Current: 10.63

-0.31
24.74
ROA (%) 5.29
HSP's ROA (%) is ranked higher than
79% of the 930 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.82 vs. HSP: 5.29 )
HSP' s 10-Year ROA (%) Range
Min: -0.16   Max: 13.13
Current: 5.29

-0.16
13.13
ROC (Joel Greenblatt) (%) 17.81
HSP's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.02 vs. HSP: 17.81 )
HSP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 0.67   Max: 53.84
Current: 17.81

0.67
53.84
Revenue Growth (3Y)(%) 1.50
HSP's Revenue Growth (3Y)(%) is ranked higher than
67% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. HSP: 1.50 )
HSP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -0.9   Max: 12.4
Current: 1.5

-0.9
12.4
EBITDA Growth (3Y)(%) -32.30
HSP's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. HSP: -32.30 )
HSP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -32.3   Max: 15.4
Current: -32.3

-32.3
15.4
» HSP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

HSP Guru Trades in Q1 2014

Jim Simons 151,800 sh (+284.3%)
Mario Gabelli 153,770 sh (+30.68%)
Vanguard Health Care Fund 8,375,170 sh (+22.69%)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Brian Rogers Sold Out
Richard Snow Sold Out
Jeff Auxier 205,530 sh (-5.75%)
John Rogers 4,127,850 sh (-11.62%)
Paul Tudor Jones 10,800 sh (-26.41%)
Steven Cohen 17,130 sh (-55.51%)
» More
Q2 2014

HSP Guru Trades in Q2 2014

Mario Gabelli 204,370 sh (+32.91%)
Jim Simons 182,900 sh (+20.49%)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Vanguard Health Care Fund 8,375,170 sh (unchged)
Jeff Auxier 181,463 sh (-11.71%)
John Rogers 3,130,809 sh (-24.15%)
Paul Tudor Jones 7,700 sh (-28.7%)
» More
Q3 2014

HSP Guru Trades in Q3 2014

Joel Greenblatt 313,242 sh (New)
Paul Tudor Jones 24,894 sh (+223.3%)
Jim Simons 323,100 sh (+76.65%)
Mario Gabelli 254,870 sh (+24.71%)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Vanguard Health Care Fund 8,375,170 sh (unchged)
John Rogers 2,433,369 sh (-22.28%)
Jeff Auxier 127,307 sh (-29.84%)
» More
Q4 2014

HSP Guru Trades in Q4 2014

Jim Simons 631,695 sh (+95.51%)
Mario Gabelli 352,370 sh (+38.25%)
Michael Price 400,000 sh (unchged)
Robert Bruce 10,000 sh (unchged)
Joel Greenblatt Sold Out
Jeff Auxier 126,907 sh (-0.31%)
Vanguard Health Care Fund 7,966,970 sh (-4.87%)
John Rogers 2,311,309 sh (-5.02%)
Paul Tudor Jones 19,798 sh (-20.47%)
» More
» Details

Insider Trades

Latest Guru Trades with HSP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-12-31 Sold Out 0.16%$48.12 - $62.84 $ 87.7155%0
Mario Gabelli 2014-12-31 Add 38.25%0.03%$48.12 - $62.84 $ 87.7155%352370
John Rogers 2014-09-30 Reduce -22.28%0.45%$49.59 - $56.21 $ 87.7165%2433369
Joel Greenblatt 2014-09-30 New Buy0.16%$49.59 - $56.21 $ 87.7165%313242
Mario Gabelli 2014-09-30 Add 24.71%0.01%$49.59 - $56.21 $ 87.7165%254870
John Rogers 2014-06-30 Reduce -24.15%0.53%$42.14 - $52.41 $ 87.7185%3130809
Mario Gabelli 2014-06-30 Add 32.91%0.01%$42.14 - $52.41 $ 87.7185%204370
Richard Snow 2014-03-31 Sold Out 1.3%$40.89 - $45 $ 87.71105%0
Brian Rogers 2014-03-31 Sold Out 0.37%$40.89 - $45 $ 87.71105%0
John Rogers 2014-03-31 Reduce -11.62%0.28%$40.89 - $45 $ 87.71105%4127850
Vanguard Health Care Fund 2014-03-31 Add 22.69%0.18%$40.89 - $45 $ 87.71105%8375170
Mario Gabelli 2014-03-31 Add 30.68%0.01%$40.89 - $45 $ 87.71105%153770
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Hospira Inc

John Rogers Comments on Hospira Inc. - Jul 25, 2013

Injectible drug specialist Hospira, Inc. (HSP) shot up +16.69% on good and surprising news about a new compound. Specifically, its Inflectra drug—a biosimilar medicine to Remicade— was recommended for approval by a crucial European authority for multiple treatments. In Europe, it is likely to be approved to treat rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. Typically, a drug is only approved for one condition first and then may receive other indications over time. Given Remicade had sales of roughly $2 billion in Europe last year, this was huge news. In recent quarters, there has been such a tight focus on existing facilities and historical problems that few have looked to the future. Our point of view has been the issues will get fixed and the company will go on to create new and better compounds to continue to drive growth; it seems the market needed a reminder such a future was even possible.

From John RogersAriel Fund Second Quarter 2013 Commentary.


Check out John Rogers latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 45.20
HSP's P/E(ttm) is ranked higher than
77% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 48.60 vs. HSP: 45.20 )
HSP' s 10-Year P/E(ttm) Range
Min: 8.48   Max: 133.97
Current: 45.2

8.48
133.97
Forward P/E 26.95
HSP's Forward P/E is ranked higher than
84% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 58.14 vs. HSP: 26.95 )
N/A
PE(NRI) 45.20
HSP's PE(NRI) is ranked higher than
77% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 48.50 vs. HSP: 45.20 )
HSP' s 10-Year PE(NRI) Range
Min: 8.48   Max: 135
Current: 45.2

8.48
135
P/B 4.40
HSP's P/B is ranked higher than
67% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. HSP: 4.40 )
HSP' s 10-Year P/B Range
Min: 1.52   Max: 5.83
Current: 4.4

1.52
5.83
P/S 3.30
HSP's P/S is ranked higher than
76% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. HSP: 3.30 )
HSP' s 10-Year P/S Range
Min: 0.99   Max: 3.35
Current: 3.3

0.99
3.35
PFCF 88.60
HSP's PFCF is ranked higher than
84% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. HSP: 88.60 )
HSP' s 10-Year PFCF Range
Min: 8.32   Max: 203.78
Current: 88.6

8.32
203.78
POCF 25.12
HSP's POCF is ranked higher than
83% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.53 vs. HSP: 25.12 )
HSP' s 10-Year POCF Range
Min: 5.95   Max: 50.76
Current: 25.12

5.95
50.76
EV-to-EBIT 24.95
HSP's EV-to-EBIT is ranked higher than
77% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.09 vs. HSP: 24.95 )
HSP' s 10-Year EV-to-EBIT Range
Min: -1403.5   Max: 508.2
Current: 24.95

-1403.5
508.2
Shiller P/E 68.70
HSP's Shiller P/E is ranked higher than
77% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 103.75 vs. HSP: 68.70 )
HSP' s 10-Year Shiller P/E Range
Min: 12.55   Max: 68.7
Current: 68.7

12.55
68.7
Current Ratio 2.36
HSP's Current Ratio is ranked higher than
70% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.36 vs. HSP: 2.36 )
HSP' s 10-Year Current Ratio Range
Min: 1.61   Max: 3.03
Current: 2.36

1.61
3.03
Quick Ratio 1.34
HSP's Quick Ratio is ranked higher than
65% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. HSP: 1.34 )
HSP' s 10-Year Quick Ratio Range
Min: 1   Max: 2.04
Current: 1.34

1
2.04
Days Inventory 141.86
HSP's Days Inventory is ranked higher than
72% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.90 vs. HSP: 141.86 )
HSP' s 10-Year Days Inventory Range
Min: 47.38   Max: 136.04
Current: 141.86

47.38
136.04
Days Sales Outstanding 50.37
HSP's Days Sales Outstanding is ranked higher than
88% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.97 vs. HSP: 50.37 )
HSP' s 10-Year Days Sales Outstanding Range
Min: 43.91   Max: 59.38
Current: 50.37

43.91
59.38

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.00
HSP's Price/Tangible Book is ranked higher than
65% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.29 vs. HSP: 7.00 )
HSP' s 10-Year Price/Tangible Book Range
Min: 3.04   Max: 20.95
Current: 7

3.04
20.95
Price/DCF (Projected) 3.10
HSP's Price/DCF (Projected) is ranked higher than
84% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.24 vs. HSP: 3.10 )
HSP' s 10-Year Price/DCF (Projected) Range
Min: 0.91   Max: 1.85
Current: 3.1

0.91
1.85
Price/Median PS Value 1.70
HSP's Price/Median PS Value is ranked higher than
64% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. HSP: 1.70 )
HSP' s 10-Year Price/Median PS Value Range
Min: 0.61   Max: 1.36
Current: 1.7

0.61
1.36
Price/Graham Number 3.70
HSP's Price/Graham Number is ranked higher than
76% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.07 vs. HSP: 3.70 )
HSP' s 10-Year Price/Graham Number Range
Min: 1.85   Max: 9.99
Current: 3.7

1.85
9.99
Earnings Yield (Greenblatt) 4.00
HSP's Earnings Yield (Greenblatt) is ranked higher than
76% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. HSP: 4.00 )
HSP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 10
Current: 4

0.2
10
Forward Rate of Return (Yacktman) -4.82
HSP's Forward Rate of Return (Yacktman) is ranked higher than
64% of the 527 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.94 vs. HSP: -4.82 )
HSP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.6   Max: 18.4
Current: -4.82

-1.6
18.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:HOS.Germany,
Hospira, Inc. was incorporated in Delaware on September 16, 2003. The Company is a provider of injectable drugs and infusion technologies. Its portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. The Company conducts operations and is managed in three reportable segments: Americas; Europe, Middle East and Africa; and Asia Pacific. The Americas segment includes the United States, Canada and Latin America; the EMEA segment includes Europe, the Middle East and Africa; and the APAC segment includes Asia, Japan, Australia and New Zealand. The Company offers Specialty injectable pharmaceutical, Medication management & other pharmaceuticals. The Company's specialty injectable pharmaceutical product category mainly consists of generic injectable pharmaceuticals. These products provide customers with a lower-cost alternative to branded products, when the patent protection has expired, when patents have been declared invalid, or when the products do not infringe the patents of others. These drugs' therapeutic areas include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other areas. The Company's other pharmaceuticals mainly consist of large volume I.V. solution, nutritional and contract manufacturing services. The Company offers infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for the washing and cleansing of wounds or surgical sites. Its contract manufacturing services are offered through its One2One(SM) services group. The Company's medication management products include electronic drug delivery pumps, safety software and disposable administration sets dedicated to the company's pumps. These sets are used to deliver I.V. fluids and medications. Medication management includes TheraDoc, Inc. products, which are module-based clinical surveillance systems that provide patient safety surveillance and clinical decision support. Medication management also includes gravity administration sets and other device products, including needlestick safety products and programs to support Hospira's customers. The Company's main customers in the Americas segment include hospitals, wholesalers, integrated delivery networks and alternate site facilities. Its main customers in the EMEA and APAC segments are hospitals and wholesalers that serve through its own sales force and its distributors. In the U.S., the Company's products are mainly distributed through a network of Company-operated distribution facilities and third-party logistics providers. The Company's competitors in specialty injectable pharmaceuticals in the Americas segment include Baxter International Inc., Bedford Laboratories, Fresenius Kabi, Pfizer, Sandoz
» More Articles for HSP

Headlines

Articles On GuruFocus.com
Hospira’s Q4 Earnings Were Bright, Though Acquisition Is In The Cards Feb 19 2015 
Analysts Weigh in on Pfizer Following Acquisition Announcement of Hospira Feb 06 2015 
Feeling Good With This Med Company Jan 20 2015 
Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
Weekly CFO Sells Highlight: Hospira Inc, Rockwood Holdings Inc, Mylan Inc. Nov 30 2014 
Jeff Auxier Second Quarter Shareholder Letter Aug 08 2014 
Brian Rogers' T. Rowe Price Equity Income Fund Semi-Annual Report 2013 Dec 02 2013 
Ariel Capital's John Rogers Trims Sotheby’s, DeVry, Hospira, IPG, Others Nov 18 2013 
Five Companies Cut - Pzena Investment Management Update Nov 12 2013 
John Rogers Comments on Hospira Inc. Jul 25 2013 

More From Our Partners
3 Best Performing Stocks in February - Analyst Blog Mar 2 2015 - ZACKS

More From Other Websites
Increased Mergers and Acquistions Help, But Headwinds Persist Feb 27 2015
Stock Goes Nuts As Akorn Cracks Q4 EPS, '15 Views Feb 26 2015
FDA postpones key hearing on biosimilar copy of blockbuster drug Feb 26 2015
[$$] Generic Copies of Remicade Go on Sale in Europe Feb 26 2015
Biosimilar copies of blockbuster drug launch in major EU markets Feb 25 2015
Biosimilar copies of blockbuster drug launch in major EU markets Feb 25 2015
Hospira and Celltrion launch biosimilars Feb 24 2015
Pfizer Rapamune Under FDA Priority Review for Lung Disease - Analyst Blog Feb 23 2015
UPDATE - INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Hospira Inc. of Class Action... Feb 23 2015
Peterson's top sectors Feb 23 2015
Hot Dividend Stocks: Pfizer Pulls Back Into Buy Range Feb 19 2015
The Medicines Co. Earnings Down Y/Y, Angiomax Sales Grow - Analyst Blog Feb 19 2015
Inflectra™ (infliximab) patient registry reports interim results in the treatment of inflammatory... Feb 19 2015
HOSPIRA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Feb 18 2015
HOSPIRA INC Financials Feb 18 2015
HOSPIRA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of the Hospira, Inc.... Feb 17 2015
Hospira Launches Inflectra, Remicade Biosimilar, in Europe - Analyst Blog Feb 17 2015
Pfizer NDA on Pain Management Candidate Accepted by FDA - Analyst Blog Feb 17 2015
Investor Lawsuit Against Acquisition of Hospira, Inc. (HSP) Announced by Shareholders Foundation Feb 17 2015
Deja vu all over again: Staples and Office Depot attempt a merger Feb 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK